Showing 2762 results
- Media Release /More than 27,000 Novartis associates worldwide dedicate an estimated 200,000 hours to volunteer with charitable causes in their communities Community Partnership Day symbolizes the company'…
- Media Release /Die fortzuführenden Geschäftsbereiche[1] steigern im ersten Quartal den Umsatz, das operative Kernergebnis[2] und den Kerngewinn pro Aktie (kWk[2]) Der Nettoumsatz beläuft sich auf USD 11,9…
- Media Release /Ventes, résultat opérationnel core[2] et BPA core (tcc[2]) des activités poursuivies[1] en hausse au T1 Chiffre d'affaires net s'élevant à USD 11,9 milliards (-7%, +3% tcc)]2] Résultat…
- Media Release /Continuing operations[1] saw sales, core[2] operating income and core EPS grow (cc[2]) in Q1 Net sales were USD 11.9 billion (-7%, +3% cc)[2] Operating income was USD 2.8 billion (-1%, +15% cc)…
- Media Release /Zykadia (ceritinib) is the first treatment option approved for patients in Europe with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib Marketing authorization was based on…
- Media Release /Positive top-line results seen with Arzerra plus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) patients when initial treatment stopped working CLL is the most…
- Media Release /Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results will be submitted for presentation at…
- Media Release /QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] GEM 1 & 2 studies…
- Media Release /Overall survival data for Tafinlar® and Mekinist® combination to be presented in metastatic BRAF V600E/K mutation-positive cutaneous melanoma New data for Zykadia® in ALK+ non-small cell…
- Media Release /In Phase II studies, Zykadia (ceritinib) shrank tumors in patients with ALK+ NSCLC; comparable overall response in those with or without brain metastases[1],[2] Tafinlar (dabrafenib) and…
Pagination
- ‹ Previous page
- 1
- …
- 241
- 242
- 243
- 244
- 245
- 246
- 247
- …
- 277
- › Next page